Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MMP12 | P39900 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29893671 | 1.00 | PKM (0.59) | PKMSMN1; SMN2MMP12KMT2AMEN1 | |
| SCHEMBL1744758 | 0.84 | PKM (0.59) | PKMSMN1; SMN2MMP12KMT2AMEN1 | |
| SCHEMBL707964 | 0.84 | PKM (0.59) | PKMSMN1; SMN2MMP12KMT2AMEN1 | |
| SCHEMBL30197829 | 0.84 | SMN1; SMN2 (0.62) | PKMSMN1; SMN2MMP12KMT2AMEN1 | |
| SCHEMBL707711 | 0.84 | SMN1; SMN2 (0.62) | PKMSMN1; SMN2MMP12KMT2AMEN1 | |
| SCHEMBL706059 | 0.82 | PARP1 (0.62) | PKMSMN1; SMN2MMP12KMT2AMEN1 | |
| SCHEMBL532240 | 0.81 | GAA (0.65) | PKMKMT2AMEN1LMNARXFP1 | |
| SCHEMBL10154038 | 0.81 | SMN1; SMN2 (0.69) | PKMSMN1; SMN2MMP12KMT2AMEN1 | |
| SCHEMBL20364687 | 0.81 | SMN1; SMN2 (0.58) | PKMSMN1; SMN2MMP12KMT2AMEN1 | |
| SCHEMBL2898736 | 0.81 | PKM (0.59) | PKMSMN1; SMN2MMP12KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | claimed |
| US-8372840-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2013-02-12 | — | — | US | claimed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| US-7491714-B2 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-02-17 | — | — | US | claimed |
| EP-1567520-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2008-10-15 | — | — | EP | claimed |
| EP-1567520-A4 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-08-02 | — | — | EP | claimed |
| JP-2006515862-A | — | — | 2006-06-08 | — | — | JP | claimed |
| US-20060116512-A1 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-06-01 | — | — | US | claimed |
| EP-1567520-A2 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | claimed |
| WO-2004050036-A2 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | claimed |
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-8372840-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2013-02-12 | — | — | US | disclosed |
| EP-2334637-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1567520-A4 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20060116512-A1 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-06-01 | — | — | US | disclosed |
| EP-1567520-A2 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050036-A2 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087438-A1 | New Potassium Channel Blockers | KCNJ2, KCNB1, KCNJ11 | PKM 444/4885SMN1; SMN2 3819/4885MMP12 4750/4885 |
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | TOP2A, TOP1, TOP2B | PKM 3138/4885SMN1; SMN2 4553/4885MMP12 1798/4885 |
| US-20060116512-A1 | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents | NQO2, NQO1, NPM1 | PKM 3647/4885SMN1; SMN2 3234/4885MMP12 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.